Why the Little Green Pharma (ASX:LGP) share price is edging higher

The Little Green Pharma (ASX: LGP) share price is on the move after news the company's medicinal cannabis products will be sold in Denmark.

| More on:
cannabis leaves on a rising line graph representing growth of ASX cannabis share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Little Green Pharma Ltd (ASX: LGP) shares are on the rise this morning following the company's announcement of a new European distribution deal. The Australian medicinal cannabis manufacturer has signed an agreement that will see its products sold in Denmark. At the time of writing, the Little Green Pharma share price is trading 1.31% higher at 77.5 cents.

Let's look closer at the company's latest news.

Distribution in Denmark

Little Green Pharma has signed a 5-year, non-exclusive distribution agreement with Balancial Danmark ApS.

The agreement will see Balancial distributing Little Green Pharma-branded cannabis oil and flower medicines in the Scandinavian nation.

According to the company's release, the deal is another step in its plan to grow its market share in key European medicinal cannabis markets.

It has already nabbed entry points into Germany, France, and the United Kingdom.

The agreement comes with certain terms and conditions. One being that Balancial cannot market or manufacture any other cannabis oil or flower products in Denmark until it has ordered 20,000 units from the Australian company.

 Another is that the Danish company must order at least 2,000 units per shipment, on a continuous basis.

Denmark is currently more than 3 years into a 4-year trial period for the use of medicinal cannabis products. Within the trial, medicinal cannabis prescriptions are 50% reimbursed (up to US$1,500 per year) by the state, and fully reimbursed for terminally ill patients.

Little Green Pharma states, since the trial's introduction, medicinal cannabis patient count and prescription volumes have been growing quickly. As of February 2020, the market was expected to be worth 500 million euros and represent 2% of the population by maturity.

Commentary from management

Little Green Pharma's managing director Fleta Solomon commented on the agreement:

LGP is pleased to announce another agreement for the distribution of LGP products into a prospective EU medicinal cannabis marketplace, and looks forward to collaborating with Balancial to help service our future Danish customers.

Little Green Pharma share price snapshot

The Little Green Pharma share price has been performing well on the ASX lately.

Currently, the company's share price is up by around 38% year to date. It's also up by around 158% over the last 12 months.

The company has a market capitalisation of around $101 million, with approximately 187 million shares outstanding.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Cannabis Shares

A man in a horse head mask and suit jumps for joy on a beach.
Cannabis Shares

Could ASX cannabis shares be set for a smoking hot rebound?

ASX cannabis stocks could be set for a strong finish to 2024.

Read more »

Man in a cannabis greenhouse looks unhappy and puts his thumb down.
Cannabis Shares

Why are these 2 ASX cannabis stocks sputtering today?

Up 174% in 2023, this ASX cannabis share is giving back some more of its gains today.

Read more »

A young male investor wearing a white business shirt screams in frustration with his hands grasping his hair after ASX 200 shares fell rapidly today and appear to be heading into a stock market crash
Cannabis Shares

Guess which ASX cannabis share is crashing 36% following an FDA blow

Rookie mistake: This cannabis share just missed out on FDA approval for a simple reason.

Read more »

A Cronos Australia farmer and ASX cannabis shares investor stands in a field of cannabis plants and smiles at the camera
Cannabis Shares

Could ASX cannabis shares be set for a resurgence?

The world's legal and medical fraternities are taking small steps forward in the medicinal cannabis movement.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Cannabis Shares

This ASX cannabis stock is up 160% since June, and it has an FDA ruling coming up!

Investors are very excited about this cannabis stock.

Read more »

two men in formal business clothing closely inspect a bud from a cannabis crop.
Cannabis Shares

Why ASX cannabis shares just jumped back into the spotlight

ASX cannabis shares operate in a nation where medical marijuana is legal but recreational use remains broadly forbidden.

Read more »

A hip young man with a beard and manbun sits thoughtfully at his laptop computer in a darkened room, staring at the screen with his chin resting on his hand in thought.
Cannabis Shares

Should I buy Incannex shares while they're at multi-year lows, or steer clear?

Is the cannabis-based pharma company a bargain buy right now?

Read more »

Man in the green house growing medical cannabis
Cannabis Shares

A $3k investment in ASX cannabis stock Incannex 5 years ago is now worth $15,000. Here's why

This medicinal cannabis company has been a rare winner in its field.

Read more »